December 2002
Volume 43, Issue 13
ARVO Annual Meeting Abstract  |   December 2002
Tissue-Specific Up-Regulation of B7 Expression During Experimental Autoimmune Anterior Uveitis (EAAU)
Author Affiliations & Notes
  • H Shao
    Department of Ophthalmology University of Louisville Louisville KY
  • D Sun
    Louisville KY
  • SL Sun
    Louisville KY
  • N Bora
    Louisville KY
  • HJ Kaplan
    Louisville KY
  • Footnotes
    Commercial Relationships   H. Shao, None; D. Sun , None; S.L. Sun , None; N. Bora , None; H.J. Kaplan , None. Grant Identification: NIH EY 12974, 13094 and 10543, RPB and Commonwealth of Kentucky Research Challenge Trust Fund
Investigative Ophthalmology & Visual Science December 2002, Vol.43, 1550. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      H Shao, D Sun, SL Sun, N Bora, HJ Kaplan; Tissue-Specific Up-Regulation of B7 Expression During Experimental Autoimmune Anterior Uveitis (EAAU) . Invest. Ophthalmol. Vis. Sci. 2002;43(13):1550.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Abstract: : Purpose:Several studies have demonstrated the up-regulation of B7.2 before B7-1 on antigen presenting cells (APCs), including B cells and dendritic cells, after in vitro culture. Few studies have examined the expression of these cell surface molecules during the course of an immune response in vivo. We investigated the kinetics of expression of B7.1 and B7.2, as well as which cell in the iris/ciliary body ICB) expressed these molecules, during the course of clinical disease. Methods:EAAU was generated in Lewis rats by immunization with melanin-associated antigen. Eyes were collected at different stages of disease, the anterior segment removed and digested enzymaticly to form single cell suspensions. The cells were double labeled with FITC-conjugated CD3, MHC II or ED2 antibodies and purified anti B7.1 or B7.2 antibodies followed by PE-conjugated anti-mouse IgG. Samples were analyzed by flow cytometry. Results:B7.1 and B7.2 are minimally expressed in the normal eye. B7.2, but not B7.1, was detected in the eye prior to the onset of inflammation - on day 8 (i.e. at the time of cellular infiltration on light microscopy and before the onset of clinical disease). However, both B7.1 and B7.2 are markedly augmented during the acute phase of the disease. Interestingly, B7.1 and B7.2 positive cells were reduced during remission, although inflammatory infiltrates were still present in the ICB. We analyzed individual cell subsets, including infiltrated T cells, MHC class II positive cells and resident macrophages in the eye at the onset of disease. We found that MHC II positive cells were significantly increased from normal (2% to 37%) and expressed B7.1 and B7.2 highly. ED2 positive cells, i.e. resident macrophages, were only slightly increased compared to the resting state (i.e. 1.5%) and expressed B7.1 and B7.2 at the onset of disease as well. Conclusion:B7.2 is expressed before B7.1 in the eye during the onset of uveits. However, the evolution of intraocular inflammation require both B7.1 and B7.2. Cells expressing MHC class II molecules are significantly enhanced during the onset of disease and are probably efficient antigen presenting cells since they express highly B7 molecules.

Keywords: 320 antigen presentation/processing • 318 anterior segment • 327 autoimmune disease 

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.